MCRB - Seres Therapeutics Inc

MCRB - Seres Therapeutics Inc

https://www.serestherapeutics.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

All You Need to Know About Seres Therapeutics ( MCRB ) Rating Upgrade to Buy

Zacks Commentary • 5 days, 23 hours ago • score: 0.35

Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seres Therapeutics ( MCRB ) 's Technical Outlook is Bright After Key Golden Cross

Zacks Commentary • 2 weeks, 4 days ago • score: 0.55

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 2 weeks, 5 days ago • score: 0.23

CAMBRIDGE, Mass., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Seres Therapeutics, Inc. ( Nasdaq: MCRB ) , a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at ...

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - Seres Therapeutics ( NASDAQ:MCRB )

Benzinga • 1 month, 3 weeks ago • score: 0.21

CAMBRIDGE, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Seres Therapeutics, Inc. MCRB, a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and ...

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

GlobeNewswire • 1 month, 3 weeks ago • score: 0.22

CAMBRIDGE, Mass., July 22, 2025 ( GLOBE NEWSWIRE ) -- Seres Therapeutics, Inc. ( Nasdaq: MCRB ) , a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company is headquartered in Cambridge, Massachusetts.

52W High

$24.20

52W Low

$6.53

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.16

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

10.26

EV/EBITDA (<8 favorable)

-2.07

EV/Revenue (<3 favorable)

805.87

P/S (TTM) (<3 favorable)

390.27

P/B (<3 favorable)

5.14

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

12.94%

Institutions (25–75% balanced)

26.03%

Shares Outstanding

8,754,600

Float

6,459,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

126,325,000

Gross Profit (TTM)

-9,204,000

EPS (TTM)

-6.79

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-15.56%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.93

Momentum

Bearish momentum

Value

0.6959

Previous

1.0822

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025